Research programme: hemojuvelin antagonist monoclonal antibodies - Disc Medicine/AbbVie
Alternative Names: Anti-hemojuvelin antibody 1; Anti-hemojuvelin antibody 2Latest Information Update: 28 Nov 2023
At a glance
- Originator AbbVie
- Developer Disc Medicine
- Class Antianaemics; Monoclonal antibodies
- Mechanism of Action HFE2 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anaemia; Myeloproliferative disorders
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Anaemia in USA (Parenteral)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Myeloproliferative disorders in USA (Parenteral)
- 13 Oct 2020 Disc Medicine plans a clinical trial for Anaemia and Myeloproliferative disorders